Last reviewed · How we verify
Arm A - Olaparib
Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage.
Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage. Used for Maintenance treatment of platinum-sensitive relapsed ovarian cancer, Maintenance treatment of platinum-sensitive relapsed, BRCA mutated, advanced ovarian cancer.
At a glance
| Generic name | Arm A - Olaparib |
|---|---|
| Also known as | AZD-2281 |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | PARP inhibitor |
| Target | PARP1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PARP1, olaparib causes DNA damage in cancer cells, leading to cell death. This mechanism is particularly effective in cancers with BRCA1 or BRCA2 mutations, which are defective in DNA repair.
Approved indications
- Maintenance treatment of platinum-sensitive relapsed ovarian cancer
- Maintenance treatment of platinum-sensitive relapsed, BRCA mutated, advanced ovarian cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
- Anemia
- Thrombocytopenia
Key clinical trials
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (PHASE2)
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PHASE2)
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (PHASE2)
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |